$CYN
Cyngn Inc.

2023 Q2 Form 10-Q Financial Statement

#000121390023038531 Filed on May 11, 2023

View on sec.gov

Income Statement

Concept 2023 Q2 2023 Q1 2022 Q1
Revenue $551.0K $872.8K
YoY Change
Cost Of Revenue $462.6K $616.7K
YoY Change
Gross Profit $88.33K $256.1K $0.00
YoY Change
Gross Profit Margin 16.03% 29.34%
Selling, General & Admin $2.846M $3.071M $2.138M
YoY Change 20.73% 43.67%
% of Gross Profit 3221.99% 1199.08%
Research & Development $3.738M $3.030M $1.681M
YoY Change 65.71% 80.24%
% of Gross Profit 4231.75% 1183.13%
Depreciation & Amortization $93.04K $228.0K $69.05K
YoY Change 282.4% 230.24%
% of Gross Profit 105.33% 89.04%
Operating Expenses $3.738M $3.030M $3.819M
YoY Change -18.97% -20.65%
Operating Profit -$6.495M -$5.845M -$3.819M
YoY Change 40.81% 53.06%
Interest Expense $18.89K $46.90K -$380.00
YoY Change -1273.29% -12442.11%
% of Operating Profit
Other Income/Expense, Net $142.0K $216.1K $0.00
YoY Change 14817.33%
Pretax Income -$6.353M -$5.629M -$3.819M
YoY Change 37.76% 47.39%
Income Tax $0.00 $0.00 $0.00
% Of Pretax Income
Net Earnings -$6.353M -$5.629M -$3.819M
YoY Change 37.76% 47.39%
Net Earnings / Revenue -1153.17% -644.91%
Basic Earnings Per Share -$0.19 -$0.17 -$0.14
Diluted Earnings Per Share -$0.19 -$0.17 -$142.2K
COMMON SHARES
Basic Shares Outstanding 33.83M shares 33.72M shares 26.86M shares
Diluted Shares Outstanding 33.79M shares 33.70M shares 26.86M shares

Balance Sheet

Concept 2023 Q2 2023 Q1 2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $12.12M $16.96M $18.33M
YoY Change -62.83% -7.5%
Cash & Equivalents $3.056M $7.968M $18.33M
Short-Term Investments $9.064M $8.989M
Other Short-Term Assets $1.134M $1.385M $635.9K
YoY Change 73.56% 117.82%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $13.25M $18.34M $18.97M
YoY Change -60.15% -3.3%
LONG-TERM ASSETS
Property, Plant & Equipment $1.191M $1.250M $1.086M
YoY Change 154.73% 15.15%
Goodwill
YoY Change
Intangibles $556.8K $509.3K
YoY Change 206.12%
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $2.302M $1.993M $1.116M
YoY Change 78.07% 78.58%
TOTAL ASSETS
Total Short-Term Assets $13.25M $18.34M $18.97M
Total Long-Term Assets $2.302M $1.993M $1.116M
Total Assets $15.56M $20.33M $20.08M
YoY Change -54.97% 1.25%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $305.4K $443.6K $94.69K
YoY Change 25.41% 368.48%
Accrued Expenses $181.7K $94.99K $720.1K
YoY Change 31.0% -86.81%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change -100.0%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $1.614M $913.9K $816.7K
YoY Change 48.63% 11.91%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $228.7K
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $228.7K
YoY Change -100.0% -100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $1.614M $913.9K $816.7K
Total Long-Term Liabilities $0.00 $0.00 $228.7K
Total Liabilities $1.614M $913.9K $1.045M
YoY Change 26.52% -12.57%
SHAREHOLDERS EQUITY
Retained Earnings -$147.7M -$141.4M
YoY Change 18.24%
Common Stock $338.00 $337.00
YoY Change 0.6%
Preferred Stock
YoY Change
Treasury Stock (at cost) $9.100M $9.000M
YoY Change
Treasury Stock Shares
Shareholders Equity $13.94M $19.42M $19.04M
YoY Change
Total Liabilities & Shareholders Equity $15.56M $20.33M $20.08M
YoY Change -54.97% 1.25%

Cashflow Statement

Concept 2023 Q2 2023 Q1 2022 Q1
OPERATING ACTIVITIES
Net Income -$6.353M -$5.629M -$3.819M
YoY Change 37.76% 47.39%
Depreciation, Depletion And Amortization $93.04K $228.0K $69.05K
YoY Change 282.4% 230.24%
Cash From Operating Activities -$4.870M -$5.377M -$3.400M
YoY Change 35.17% 58.15%
INVESTING ACTIVITIES
Capital Expenditures $34.04K $447.7K -$226.9K
YoY Change -118.56% -297.32%
Acquisitions
YoY Change
Other Investing Activities -$9.820K $3.200M
YoY Change -99.96%
Cash From Investing Activities -$43.86K $2.752M -$226.9K
YoY Change -99.84% -1312.95%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 1.230K $6.844K 88.89K
YoY Change -99.99% -92.3%
NET CHANGE
Cash From Operating Activities -4.870M -$5.377M -3.400M
Cash From Investing Activities -43.86K $2.752M -226.9K
Cash From Financing Activities 1.230K $6.844K 88.89K
Net Change In Cash -4.912M -$2.618M -3.538M
YoY Change -61.64% -26.0%
FREE CASH FLOW
Cash From Operating Activities -$4.870M -$5.377M -$3.400M
Capital Expenditures $34.04K $447.7K -$226.9K
Free Cash Flow -$4.904M -$5.825M -$3.173M
YoY Change 43.42% 83.57%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q1 dei Document Type
DocumentType
10-Q
CY2023Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2023Q1 dei Document Period End Date
DocumentPeriodEndDate
2023-03-31
CY2023Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2023Q1 dei Entity File Number
EntityFileNumber
001-40932
CY2023Q1 dei Entity Registrant Name
EntityRegistrantName
CYNGN INC.
CY2023Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2023Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
46-2007094
CY2023Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
1015 O’Brien Dr
CY2023Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Menlo Park
CY2023Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
CY2023Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
94025
CY2023Q1 dei City Area Code
CityAreaCode
(650)
CY2023Q1 dei Local Phone Number
LocalPhoneNumber
924-5905
CY2023Q1 dei Security12b Title
Security12bTitle
Common stock, $0.00001
CY2023Q1 dei Trading Symbol
TradingSymbol
CYN
CY2023Q1 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2023Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2023Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2023Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2023Q1 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2023Q1 dei Entity Shell Company
EntityShellCompany
false
CY2023Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
33826823 shares
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
7967979 usd
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
10536273 usd
CY2022Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
50000 usd
CY2023Q1 us-gaap Short Term Investments
ShortTermInvestments
8988753 usd
CY2022Q4 us-gaap Short Term Investments
ShortTermInvestments
12064337 usd
CY2023Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1384996 usd
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1126137 usd
CY2023Q1 us-gaap Assets Current
AssetsCurrent
18341728 usd
CY2022Q4 us-gaap Assets Current
AssetsCurrent
23776747 usd
CY2023Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1250276 usd
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
884000 usd
CY2023Q1 us-gaap Finance Lease Right Of Use Asset
FinanceLeaseRightOfUseAsset
233167 usd
CY2022Q4 us-gaap Finance Lease Right Of Use Asset
FinanceLeaseRightOfUseAsset
371189 usd
CY2023Q1 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
509275 usd
CY2022Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
473076 usd
CY2023Q1 us-gaap Assets
Assets
20334446 usd
CY2022Q4 us-gaap Assets
Assets
25505012 usd
CY2023Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
443599 usd
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
155943 usd
CY2023Q1 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
231735 usd
CY2022Q4 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
854920 usd
CY2023Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
238600 usd
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
376622 usd
CY2023Q1 us-gaap Liabilities
Liabilities
913934 usd
CY2022Q4 us-gaap Liabilities
Liabilities
1387485 usd
CY2023Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.00001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.00001
CY2023Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10 shares
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10 shares
CY2023Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00001
CY2023Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2023Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
33719592 shares
CY2023Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
33719592 shares
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
33684864 shares
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
33684864 shares
CY2023Q1 us-gaap Common Stock Value
CommonStockValue
337 usd
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
337 usd
CY2023Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
160778972 usd
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
159847229 usd
CY2023Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-141358797 usd
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-135730039 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
19420512 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
24117527 usd
CY2023Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
20334446 usd
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
25505012 usd
CY2023Q1 us-gaap Revenues
Revenues
872800 usd
CY2023Q1 us-gaap Cost Of Revenue
CostOfRevenue
616694 usd
CY2023Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3030056 usd
CY2022Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1681145 usd
CY2023Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3070920 usd
CY2022Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2137516 usd
CY2023Q1 us-gaap Costs And Expenses
CostsAndExpenses
6717670 usd
CY2022Q1 us-gaap Costs And Expenses
CostsAndExpenses
3818661 usd
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-5844870 usd
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-3818661 usd
CY2023Q1 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
46902 usd
CY2022Q1 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
-379 usd
CY2023Q1 us-gaap Other Income
OtherIncome
169210 usd
CY2022Q1 us-gaap Other Income
OtherIncome
1 usd
CY2023Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
216112 usd
CY2022Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-378 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-5628758 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-3819039 usd
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.17
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.14
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
33702767 shares
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
26862227 shares
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
22247562 usd
CY2022Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
88885 usd
CY2022Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
520142 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-3819039 usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
19037550 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
24117527 usd
CY2023Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
6844 usd
CY2023Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
924898 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-5628758 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
19420512 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-5628758 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-3819039 usd
CY2023Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
228031 usd
CY2022Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
69054 usd
CY2023Q1 us-gaap Share Based Compensation
ShareBasedCompensation
924899 usd
CY2022Q1 us-gaap Share Based Compensation
ShareBasedCompensation
520142 usd
CY2023Q1 us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
169210 usd
CY2023Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
258859 usd
CY2022Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
808350 usd
CY2023Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
287656 usd
CY2022Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-17583 usd
CY2023Q1 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-761207 usd
CY2022Q1 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
655546 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-5377448 usd
CY2022Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-3400230 usd
CY2023Q1 us-gaap Payments To Acquire Equity Method Investments
PaymentsToAcquireEquityMethodInvestments
447739 usd
CY2022Q1 us-gaap Payments To Acquire Equity Method Investments
PaymentsToAcquireEquityMethodInvestments
226906 usd
CY2023Q1 cyngn Proceed From Sale Of Other Productive Assets
ProceedFromSaleOfOtherProductiveAssets
44745 usd
CY2023Q1 us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
10497206 usd
CY2023Q1 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
13742000 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
2752310 usd
CY2022Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-226906 usd
CY2023Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
6844 usd
CY2022Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
88885 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
6844 usd
CY2022Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
88885 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-2618294 usd
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-3538251 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
10586273 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
21995981 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
7967979 usd
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
18457730 usd
CY2022Q1 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
824292 usd
CY2022Q1 us-gaap Stock Issued1
StockIssued1
58676 usd
CY2023Q1 cyngn Acquisition Property And Equipment Included In Accounts Payable And Accrued Expenses
AcquisitionPropertyAndEquipmentIncludedInAccountsPayableAndAccruedExpenses
139568 usd
CY2023Q1 us-gaap Conversion Of Stock Description
ConversionOfStockDescription
Pursuant to the Purchase Agreement, the Company sold (i) 3,790,322 shares of its Common Stock together with Common Warrants to purchase up to 3,790,322 shares of Common Stock, and (ii) 2,661,291 Pre-Funded Warrants with each Pre-Funded Warrant exercisable for one share of Common Stock, together with Common Warrants to purchase up to 2,661,291 shares of Common Stock.
CY2023Q1 us-gaap Sale Of Stock Price Per Share
SaleOfStockPricePerShare
3.09
CY2023Q1 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
2.98
CY2023Q1 us-gaap Long Term Debt Term
LongTermDebtTerm
P5Y
CY2023Q1 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
5700000 usd
CY2022Q1 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
3800000 usd
CY2023Q1 us-gaap Retained Earnings Appropriated
RetainedEarningsAppropriated
141400000 usd
CY2022Q4 us-gaap Retained Earnings Appropriated
RetainedEarningsAppropriated
135700000 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
5400000 usd
CY2022Q1 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
3400000 usd
CY2023Q1 us-gaap Use Of Estimates
UseOfEstimates
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Use of Estimates</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The preparation of financial statements in conformity with GAAP requires management to make certain estimates and assumptions. These estimates and assumptions affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the balance sheet date, as well as reported amounts of revenue and expenses during the reporting period. The Company’s significant estimates and judgments include but are not limited to warrants and share-based compensation. Management bases its estimates on historical experience and on various other assumptions believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities. Actual results could differ from those estimates.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i> </i></b></p>
CY2023Q1 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Concentration of Credit Risk</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Financial instruments that potentially subject the Company to concentrations of credit risk consist of cash, which is placed with high-credit-quality financial institutions and at times exceeds federally insured limits.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Cash maintained with domestic financial institutions generally exceed the Federal Deposit Insurance Corporation insurable limit. To date, the Company has not experienced any losses on its deposits of cash. Cyngn invests in U.S. Treasury securities and carries these at amortized cost and recognizes gains and losses when realized.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p>
CY2023Q1 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
7900000 usd
CY2022Q4 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
10500000 usd
CY2022Q1 us-gaap Restricted Cash And Investments
RestrictedCashAndInvestments
126489 usd
CY2023Q1 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
7967979 usd
CY2022Q1 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
18331241 usd
CY2022Q1 us-gaap Restricted Cash
RestrictedCash
126489 usd
CY2023Q1 us-gaap Restricted Cash And Investments Current
RestrictedCashAndInvestmentsCurrent
7967979 usd
CY2022Q1 us-gaap Restricted Cash And Investments Current
RestrictedCashAndInvestmentsCurrent
18457730 usd
CY2023Q1 us-gaap Acquired Finite Lived Intangible Assets Weighted Average Useful Life
AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
P15Y
CY2022Q2 us-gaap Supplemental Deferred Purchase Price
SupplementalDeferredPurchasePrice
100000 usd
CY2022Q2 us-gaap Property Plant And Equipment Useful Life
PropertyPlantAndEquipmentUsefulLife
P15Y
CY2023Q1 cyngn Revenue Percentage
RevenuePercentage
0.768 pure
CY2023Q1 us-gaap Amount Of Deferred Costs Related To Long Term Contracts
AmountOfDeferredCostsRelatedToLongTermContracts
0 usd
CY2022Q4 us-gaap Amount Of Deferred Costs Related To Long Term Contracts
AmountOfDeferredCostsRelatedToLongTermContracts
100000 usd
CY2023Q1 us-gaap Treasury Stock Value
TreasuryStockValue
9000000 usd
CY2022Q4 us-gaap Treasury Stock Value
TreasuryStockValue
12100000 usd
CY2023Q1 cyngn Automobiles
Automobiles
399087 usd
CY2022Q4 cyngn Automobiles
Automobiles
397816 usd
CY2023Q1 us-gaap Furniture And Fixtures Gross
FurnitureAndFixturesGross
176402 usd
CY2022Q4 us-gaap Furniture And Fixtures Gross
FurnitureAndFixturesGross
176402 usd
CY2023Q1 us-gaap Property Plant And Equipment Other
PropertyPlantAndEquipmentOther
410817 usd
CY2022Q4 us-gaap Property Plant And Equipment Other
PropertyPlantAndEquipmentOther
380457 usd
CY2023Q1 us-gaap Leasehold Improvements Gross
LeaseholdImprovementsGross
192798 usd
CY2022Q4 us-gaap Leasehold Improvements Gross
LeaseholdImprovementsGross
93120 usd
CY2023Q1 us-gaap Public Utilities Property Plant And Equipment Construction Work In Progress
PublicUtilitiesPropertyPlantAndEquipmentConstructionWorkInProgress
675720 usd
CY2022Q4 us-gaap Public Utilities Property Plant And Equipment Construction Work In Progress
PublicUtilitiesPropertyPlantAndEquipmentConstructionWorkInProgress
359289 usd
CY2023Q1 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
1854824 usd
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
1407084 usd
CY2023Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
604548 usd
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
523084 usd
CY2023Q1 us-gaap Property Plant And Equipment Other Net
PropertyPlantAndEquipmentOtherNet
1250276 usd
CY2022Q4 us-gaap Property Plant And Equipment Other Net
PropertyPlantAndEquipmentOtherNet
884000 usd
CY2023Q1 us-gaap Depreciation
Depreciation
81464 usd
CY2022 us-gaap Depreciation
Depreciation
21075 usd
CY2023Q1 cyngn Credit Card Payable
CreditCardPayable
15248 usd
CY2022Q4 cyngn Credit Card Payable
CreditCardPayable
5194 usd
CY2023Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
94987 usd
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
283118 usd
CY2023Q1 us-gaap Accrued Payroll Taxes Current
AccruedPayrollTaxesCurrent
121500 usd
CY2022Q4 us-gaap Accrued Payroll Taxes Current
AccruedPayrollTaxesCurrent
566608 usd
CY2023Q1 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
231735 usd
CY2022Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
854920 usd
CY2023Q1 us-gaap Debt Instrument Periodic Payment
DebtInstrumentPeriodicPayment
47000 usd
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
240992 usd
CY2023Q1 us-gaap Receivable With Imputed Interest Net Amount
ReceivableWithImputedInterestNetAmount
2392 usd
CY2023Q1 us-gaap Present Value Of Future Minimum Lease Payments Sale Leaseback Transactions
PresentValueOfFutureMinimumLeasePaymentsSaleLeasebackTransactions
238600 usd
CY2023Q1 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P0Y5M1D
CY2023Q1 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0487 pure
CY2023Q1 us-gaap Operating Lease Expense
OperatingLeaseExpense
142586 usd
CY2022Q1 us-gaap Operating Lease Expense
OperatingLeaseExpense
78099 usd
CY2023Q1 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
138022 usd
CY2022Q1 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
47112 usd
CY2023Q1 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
553567 usd
CY2023Q1 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
-44292 usd
CY2023Q1 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
509275 usd
CY2022Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
508821 usd
CY2022Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
-35745 usd
CY2022Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
473076 usd
CY2023Q1 us-gaap Adjustment For Amortization
AdjustmentForAmortization
8547 usd
CY2022Q1 us-gaap Adjustment For Amortization
AdjustmentForAmortization
867 usd
CY2023Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2023Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00001
CY2023Q1 us-gaap Excess Stock Shares Issued
ExcessStockSharesIssued
33719592 shares
CY2023Q1 us-gaap Excess Stock Shares Outstanding
ExcessStockSharesOutstanding
33719592 shares
CY2022Q4 us-gaap Excess Stock Shares Issued
ExcessStockSharesIssued
33684864 shares
CY2022Q4 us-gaap Excess Stock Shares Outstanding
ExcessStockSharesOutstanding
33684864 shares
CY2023Q1 cyngn Warrants Outstanding
WarrantsOutstanding
6591613 shares
CY2023Q1 cyngn Fair Value
FairValue
6302833 usd
CY2023Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-5628758 usd
CY2022Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-3819039 usd
CY2023Q1 us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
33702767 shares
CY2022Q1 us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
26862227 shares
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.17
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.14
CY2023Q1 cyngn Fair Value Is Recognized
FairValueIsRecognized
The resulting fair value is recognized on a straight-line basis over the period during which an employee is required to provide service in exchange for the award. The Company has elected to recognize forfeitures as they occur. Stock options generally vest over four years and have a contractual term of ten years.
CY2023Q1 cyngn Common Stock Shares Issurance
CommonStockSharesIssurance
2800000 shares
CY2022 cyngn Common Stock Shares Issurance
CommonStockSharesIssurance
3600000 shares
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
14715110 shares
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
1.23
CY2022Q4 cyngn Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1
P7Y10M2D
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
2571013 usd
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1231000 shares
CY2023Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
1.06
CY2023Q1 cyngn Stocks Issued During Period Shares Stock Options Exercised
StocksIssuedDuringPeriodSharesStockOptionsExercised
22500 shares
CY2023Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0.3
CY2023Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
15201 usd
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
404000 shares
CY2023Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
2.04
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
15519610 shares
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
1.19
CY2023Q1 cyngn Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1
P7Y8M26D
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
6879114 usd
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
15519610 shares
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
1.19
CY2023Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P7Y8M26D
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
6879114 usd
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
6977311 shares
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
0.83
CY2023Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
P5Y9M14D
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
5504518 usd
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
216036 shares
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
5.52
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
12228 shares
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
5.52
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
203808 shares
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
5.52
CY2023Q1 cyngn Weighted Average Per Share Grantdate Fair Value Of Options Granted
WeightedAveragePerShareGrantdateFairValueOfOptionsGranted
0.57
CY2022Q1 cyngn Weighted Average Per Share Grantdate Fair Value Of Options Granted
WeightedAveragePerShareGrantdateFairValueOfOptionsGranted
0.57
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.06
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.45
CY2023Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y10D
CY2022Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y18D
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0373 pure
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0239 pure
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.525 pure
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.3615 pure
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
CY2023Q1 cyngn Stockbased Compensation Expense From Stock Options
StockbasedCompensationExpenseFromStockOptions
925000 usd
CY2022Q1 cyngn Stockbased Compensation Expense From Stock Options
StockbasedCompensationExpenseFromStockOptions
520000 usd
CY2023Q1 us-gaap Present Value Of Future Insurance Profits Weighted Average Amortization Period
PresentValueOfFutureInsuranceProfitsWeightedAverageAmortizationPeriod
P3Y3M18D
CY2023Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2022Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2023Q1 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0 pure
CY2022Q1 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0 pure
CY2022Q1 us-gaap Cost Of Revenue
CostOfRevenue
usd
CY2022Q1 us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
usd
CY2022Q1 cyngn Proceed From Sale Of Other Productive Assets
ProceedFromSaleOfOtherProductiveAssets
usd
CY2022Q1 us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
usd
CY2022Q1 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
usd
CY2023Q1 us-gaap Interest Paid Net
InterestPaidNet
usd
CY2022Q1 us-gaap Interest Paid Net
InterestPaidNet
usd
CY2022Q1 cyngn Acquisition Property And Equipment Included In Accounts Payable And Accrued Expenses
AcquisitionPropertyAndEquipmentIncludedInAccountsPayableAndAccruedExpenses
usd
CY2023Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
shares
CY2023Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
shares
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
shares
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
shares
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
26862227 shares
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
33702767 shares
CY2022Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.14
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.17
CY2023Q1 cyngn Aggregate Intrinsic Value Granted
AggregateIntrinsicValueGranted
usd
CY2023Q1 cyngn Aggregate Intrinsic Value Cancelledforfeited
AggregateIntrinsicValueCancelledforfeited
usd
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
shares
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
shares
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
CY2023Q1 dei Amendment Flag
AmendmentFlag
false
CY2023Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2023Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001874097

Files In Submission

Name View Source Status
0001213900-23-038531-index-headers.html Edgar Link pending
0001213900-23-038531-index.html Edgar Link pending
0001213900-23-038531.txt Edgar Link pending
0001213900-23-038531-xbrl.zip Edgar Link pending
cyngn-20230331.xsd Edgar Link pending
f10q0323ex31-1_cyngninc.htm Edgar Link pending
f10q0323ex31-2_cyngninc.htm Edgar Link pending
f10q0323ex32-1_cyngninc.htm Edgar Link pending
f10q0323_cyngninc.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
cyngn-20230331_cal.xml Edgar Link unprocessable
cyngn-20230331_lab.xml Edgar Link unprocessable
cyngn-20230331_pre.xml Edgar Link unprocessable
cyngn-20230331_def.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
f10q0323_cyngninc_htm.xml Edgar Link completed
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending